


REMARKS

The specification has been amended to recite the priority claims of the present application and to address various issues raised in parent application USSN 09/625,406. SEQ. ID NOs have been added to three small peptides discussed in the Background of the Invention. Editorial changes requested by the Examiner in USSN 09/625,406 have been incorporated into the present application, to facilitate prosecution. No new matter has been added by virtue of the amendments to the specification.

Applicants have cancelled all claims except claims 7-17, which correspond to Group II identified in the Restriction Requirement mailed on January 5, 1999 in the parent application, USSN 09/625,406. Claim 7 has been amended to independent form, and claims 14 and 17 have been amended to correct the antecedent basis. No new matter has been added by virtue of the amendments to the claims.

Should the Examiner wish to discuss the application, he is invited to telephone the undersigned. If any additional fees are due with respect to this submission, authorization is hereby given to charge such fees, or to credit any overpayment, to Deposit Account No. 02-1197.

Respectfully submitted,
BASF CORPORATION



Patricia A. McDaniels
Reg.No. 33,194

26 Davis Drive
Research Triangle Park, NC 27709
(919) 547-2834 (direct dial)
(919) 547-2444 (facsimile)